AbbVie To Submit European Application For Epcoritamab In Lymphoma Setting Later In 2022

• Genmab A/S (NASDAQ: GMAB) has announced that AbbVie Inc (NASDAQ: ABBV) will submit a conditional marketing authorization application with the European Medicines Agency for subcutaneous epcoritamab (DuoBody-CD3xCD20) for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), in 2H of 2022.

• Epcoritamab is an investigational bispecific antibody.

• Genmab recently announced that the company would submit a biologics license application (BLA) for epcoritamab with FDA for relapsed/refractory large B-cell lymphoma (LBCL), also in 2H of 2022.

• Related: AbbVie - Genmab Present Epcoritamab Data From Lymphoma Trial.

• The European submission is supported by results from the large b-cell lymphoma (LBCL) cohort of the pivotal EPCORE NHL-1 trial.

• Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies' oncology collaboration. The companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization.

• Price Action: ABBV shares are down 1.13% at $151.86, and GMAB is up 1.64% at $34.87 during the market session on the last check Monday.

See more from Benzinga

• The Daily Biotech Pulse: FDA Signs Off Cancer Therapy Trials For NexImmune, Omega Therapeutics, Endo To Develop Rare Hereditary Skin Disease Candidate

• New York Attorney General Says Teva Tried To Evade Accountability On Opioid Crisis: Report

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.